TRIM59 expression is regulated by Sp1 and Nrf1 in LPS-activated macrophages through JNK signaling pathway
Yanying An1, Yuqi Ni1, Zhihao Xu2
1The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, 999 Xuefu Road, Nanchang, Jiangxi 330031, China.
Abstract:
Activated macrophages play an important role in many inflammatory diseases including septic shock and atherosclerosis. TRIM59 has been showed to participate in many pathological processes, such as inflammation, cytotoxicity and tumorigenesis. However, the molecular mechanisms controlling its expression in activated macrophages are not fully understood. Here we report that TRIM59 expression is regulated by Sp1 and Nrf1 in LPS-activated macrophages. TRIM59 is highly expressed in macrophages, and markedly decreased by LPS stimuli in vivo and in vitro. TRIM59 promoter activity is also significantly suppressed by LPS and further analysis demonstrated that Sp1 and Nrf1 directly bound to the proximal promoter of TRIM59 gene. LPS treatment significantly decreased Sp1 expression, nuclear translocation and reduced its binding to the promoter, whereas increased Nrf1 expression, nuclear translocation and enhanced its binding to the promoter. Moreover, LPS-decreased TRIM59 expression was reversed by JNK inhibitor. Finally, TRIM59 level is significantly decreased during atherosclerosis progression. Taken together, our results demonstrated that TRIM59 expression was precisely regulated by Sp1 and Nrf1 in LPS-activated macrophages, which may be dependent on the activation of JNK signaling pathway and TRIM59 may be a potential therapeutic target for inflammatory diseases such as atherosclerosis.
Insights
Tumor necrosis factor superfamily member 19 (TRIM59) expression in macrophages is regulated by Sp1 and Nrf1 transcription factors. Lipopolysaccharide (LPS) stimulation decreases TRIM59, impacting inflammatory diseases like atherosclerosis.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- Activated macrophages are key players in inflammatory diseases such as septic shock and atherosclerosis.
- TRIM59 is implicated in various pathological processes including inflammation, cytotoxicity, and tumorigenesis.
- The precise molecular mechanisms governing TRIM59 expression in activated macrophages remain incompletely understood.
Purpose of the Study:
- To elucidate the regulatory mechanisms controlling TRIM59 expression in lipopolysaccharide (LPS)-activated macrophages.
- To investigate the roles of Sp1 and Nrf1 transcription factors in TRIM59 gene regulation.
- To explore the potential of TRIM59 as a therapeutic target in inflammatory conditions.
Main Methods:
- Analysis of TRIM59 expression in LPS-stimulated macrophages in vivo and in vitro.
- Luciferase reporter assays to assess TRIM59 promoter activity.
- Chromatin immunoprecipitation assays to determine Sp1 and Nrf1 binding to the TRIM59 promoter.
- Assessment of the effect of JNK pathway inhibition on TRIM59 expression.
- Evaluation of TRIM59 levels during atherosclerosis progression.
Main Results:
- TRIM59 expression and promoter activity are significantly suppressed by LPS in macrophages.
- Sp1 and Nrf1 directly bind to the proximal promoter of the TRIM59 gene.
- LPS treatment decreases Sp1 but increases Nrf1 expression, nuclear translocation, and promoter binding.
- Inhibition of the JNK signaling pathway reverses LPS-induced TRIM59 downregulation.
- TRIM59 levels are notably reduced during the progression of atherosclerosis.
Conclusions:
- TRIM59 expression in LPS-activated macrophages is precisely regulated by the opposing actions of Sp1 and Nrf1.
- This regulation is potentially mediated through the JNK signaling pathway.
- TRIM59 represents a promising therapeutic target for managing inflammatory diseases, particularly atherosclerosis.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The JAK-STAT Signaling Pathway
Regulation of Nuclear Protein Sorting


